TY - JOUR
T1 - Reliability of patient-reported outcome instruments in US adults with hemophilia
T2 - The Pain, Functional Impairment and Quality of life (P-FiQ) study
AU - Kempton, Christine L.
AU - Wang, Michael
AU - Recht, Michael
AU - Neff, Anne
AU - Shapiro, Amy D.
AU - Soni, Amit
AU - Kulkarni, Roshni
AU - Buckner, Tyler W.
AU - Batt, Katharine
AU - Iyer, Neeraj N.
AU - Cooper, David L.
N1 - Funding Information:
CL Kempton: grant/research support from Novo Nordisk Inc.; consultant for Baxter, Biogen, CSL Behring, Kedrion. M Wang: consultant for Novo Nordisk Inc.. M Recht: grant/research support from Baxter, Biogen Idec, Novo Nordisk Inc., Pfizer; consultant for Biogen, Kedrion, Novo Nordisk Inc. A Neff: grant/research support from Novo Nordisk Inc.; consultant for Alexion, Baxter, CSL Behring, Novo Nordisk Inc. AD Shapiro: consultant for Baxter BioScience, Novo Nordisk Inc., Biogen Idec, ProMetic Life Sciences, Kedrion Biopharma. A Soni: speakers bureau participant for CSL Behring and Novo Nordisk Inc.; consultant for Bayer. R Kulkarni: grant/research support from Novo Nordisk Inc., Biogen, Baxter, Bayer; consultant for Novo Nordisk Inc., Biogen, Bayer, Baxter, Kedrion, BPL, Pfizer. TW Buckner: consultant for Bax-alta US, Genentech, and Novo Nordisk Inc. K Batt: grant/ research support from Novo Nordisk Inc.; scientific advisor for Precision Health Economics. NN Iyer and DL Cooper: employees of Novo Nordisk Inc., the sponsor of the study. The authors report no other conflicts of interest in this work.
Publisher Copyright:
© 2017 Kempton et al.
PY - 2017/9/19
Y1 - 2017/9/19
N2 - Background: Hemophilia is marked by frequent joint bleeding, resulting in pain and functional impairment. Objective: This study aimed to assess the reliability of five patient-reported outcome (PRO) instruments in people with hemophilia (PWH) in a non-bleeding state. Methods: Adult male PWH of any severity and inhibitor status, with a history of joint pain or bleeding, completed a pain history and five PRO instruments (EQ-5D-5L, Brief Pain Inventory v2 [BPI], International Physical Activity Questionnaire [IPAQ], Short Form 36 Health Survey v2 [SF-36v2], and Hemophilia Activities List [HAL]) during their routine comprehensive care visit. Patients were approached to complete the PRO instruments again at the end of their visit while in a similar non-bleeding state. Concordance of individual questionnaire items and correlation between domain scores were assessed using intra-class correlation coefficient (ICC). Results: Participants completing the retest (n=164) had a median age of 33.9 years. Median time for completion of the initial survey with PRO instruments was 36.0 minutes and for the five PRO instruments, median retest time was 21.0 minutes. The majority of participants had hemophilia A (74.4%), were white and non-Hispanic (72.6%), and self-reported arthritis/bone/joint problems (61%). Median/mean test-retest concordance was EQ-5D-5L 80.0%/79.1%, BPI 54.5%/58.9%, IPAQ 100%/100%, SF-36v2 77.8%/76.4%, and HAL 77.4%/75.9%. ICCs for test-retest reliability were EQ-5D-5L index 0.890; BPI - severity 0.950; BPI - interference 0.920; IPAQ total activity 0.940; SF-36v2 overall health 0.910; HAL total score 0.970. Conclusion: All five PRO scales showed acceptable test-retest reliability in adult PWH. Therefore, the choice of instrument to be used for research or clinical care should be driven by instrument characteristics other than reliability.
AB - Background: Hemophilia is marked by frequent joint bleeding, resulting in pain and functional impairment. Objective: This study aimed to assess the reliability of five patient-reported outcome (PRO) instruments in people with hemophilia (PWH) in a non-bleeding state. Methods: Adult male PWH of any severity and inhibitor status, with a history of joint pain or bleeding, completed a pain history and five PRO instruments (EQ-5D-5L, Brief Pain Inventory v2 [BPI], International Physical Activity Questionnaire [IPAQ], Short Form 36 Health Survey v2 [SF-36v2], and Hemophilia Activities List [HAL]) during their routine comprehensive care visit. Patients were approached to complete the PRO instruments again at the end of their visit while in a similar non-bleeding state. Concordance of individual questionnaire items and correlation between domain scores were assessed using intra-class correlation coefficient (ICC). Results: Participants completing the retest (n=164) had a median age of 33.9 years. Median time for completion of the initial survey with PRO instruments was 36.0 minutes and for the five PRO instruments, median retest time was 21.0 minutes. The majority of participants had hemophilia A (74.4%), were white and non-Hispanic (72.6%), and self-reported arthritis/bone/joint problems (61%). Median/mean test-retest concordance was EQ-5D-5L 80.0%/79.1%, BPI 54.5%/58.9%, IPAQ 100%/100%, SF-36v2 77.8%/76.4%, and HAL 77.4%/75.9%. ICCs for test-retest reliability were EQ-5D-5L index 0.890; BPI - severity 0.950; BPI - interference 0.920; IPAQ total activity 0.940; SF-36v2 overall health 0.910; HAL total score 0.970. Conclusion: All five PRO scales showed acceptable test-retest reliability in adult PWH. Therefore, the choice of instrument to be used for research or clinical care should be driven by instrument characteristics other than reliability.
KW - Hemophilia
KW - Pain
KW - Patient-reported outcome
KW - Reliability
UR - http://www.scopus.com/inward/record.url?scp=85030225381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030225381&partnerID=8YFLogxK
U2 - 10.2147/PPA.S141389
DO - 10.2147/PPA.S141389
M3 - Article
AN - SCOPUS:85030225381
SN - 1177-889X
VL - 11
SP - 1603
EP - 1612
JO - Patient Preference and Adherence
JF - Patient Preference and Adherence
ER -